KRAS and colorectal carcinoma: Cells were treated with tetrac at 10−6 and 10−7 M, or combined with heteronemin at 0.4 or 0.8 μM (HT-29 cells; KRAS WT CRC) and 0.2 or 0.4 μM (HCT-116 cells; KRAS MT CRC) for 72 h (Figure 1C,D).